Brazil commits US$ 72 million to Gavi’s 2026–2030 strategic period, reinforcing its role as a key stakeholder in global health and vaccine manufacturing.

Gavi, in collaboration with global health partners, has commenced the design phase of a new maternal vaccine programme targeting RSV burden in lower-income countries.

Hungary makes first-ever pledge to Gavi, the Vaccine Alliance with EUR 1 million commitment, joining a growing group of new donors to Gavi’s 2026–2030 funding cycle.